Updated on 29 January 2013
GVK Biosciences and Endo Pharmaceuticals to jointly discover novel small molecules targeting specific proteins
Hyderabad: GVK Biosciences entered into a collaboration agreement with US-based Endo Pharmaceuticals to discover novel small molecules targeting specific proteins.
According to the agreement, GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDATM).
Mr Manni Kantipudi, CEO, GVK BIO, commented that, "We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration also confirms the value of our differentiated EDATM concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates."
Dr Sandeep Gupta, senior VP, drug discovery and early development, Endo Pharma, stated that, "We are pleased to initiate this discovery collaboration with GVK BIO. With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients."